Researchers at the University of Toronto and UC San Francisco have discovered that the intestine is the source of immune cells that reduce brain inflammation in people with multiple sclerosis (MS), and that increasing the number of these cells blocks inflammation entirely in a preclinical model of the disease.
The cells in question are plasma cells – white blood cells that originate as B cells in the bone marrow but change their behavior when triggered by microbes in the gut. Studying mice and samples from human MS patients, the researchers found that plasma cells that reside in the gut and produce Immunoglobulin A (IgA) antibodies appear to migrate to the central nervous system and produce an anti-inflammatory effect during MS flare-ups.
MS is an autoimmune disease, driven by other types of immune cells (including B and T cells) that attack myelin, the protective coating that surrounds nerve fibers. Recent clinical studies have shown drugs that target B cells mitigate MS, while those that target plasma cells make the disease worse. The current study offers an explanation for these divergent results.
“We already knew what was and was not working in the clinic,” said Jen Gommerman, PhD, a professor of immunology at the University of Toronto and the senior author on the study. “But here we’ve uncovered the molecular and cellular mechanism at play. It’s a kind of reverse translation approach, which highlights the importance of the gut-brain axis in MS and other autoimmune conditions.”
The results were published online Jan. 3, 2019, in Cell.
Canada and the U.S. have among the highest rates of MS in the world, with around three in every thousand individuals affected. Symptoms can include fatigue, poor coordination, tingling, organ problems and cognitive impairment. There is no cure, although quicker diagnoses and better drugs have improved outcomes significantly in the last 15 years.
“IgAs comprise 80 per cent of all antibodies in the body, yet their exact function is still not fully understood,” said Sergio Baranzini, PhD, a co-author on the paper who is a professor of neurology in the UCSF Weill Institute for Neurosciences. “Showing that IgA-producing B cells can travel from the gut to the brain opens a new page in the book of neuroinflammatory diseases and could be the first step towards producing novel treatments to modulate or stop MS and related neurological disorders.”
The lead authors on the work are postdoctoral fellows Olga Rojas, PhD, and Elisa Porfilio, PhD, from the Gommerman lab at the University of Toronto and Anne-Katrin Pröbstel, MD, from the Baranzini lab at UCSF. In a moment of scientific serendipity, they recently presented their research at the same conference and realized their results aligned. The researchers began to collaborate, and Pröbstel and colleagues in the Baranzini lab were able to show that the Gommerman lab’s findings in mice had parallels to human MS patients.
Specifically, the UCSF team found evidence that IgA was decreased in fecal samples from patients with active MS neuroinflammation, suggesting that the inflammation-suppressing cells had been recruited to help fight the patients’ disease.
One promising aspect of the new research is that increasing the number of IgA plasma cells that migrate from the gut to the brain eradicated neuroinflammation in mice. A therapeutic approach might aim to expand the number of these cells in the gut, enabling a plentiful supply that could move to the brain and dampen inflammation.
“As a clinician-scientist, it is exciting that our experiments linking preclinical animal models to the biology we see in real MS patients may have uncovered a general mechanism for how the immune system counteracts inflammation,” said UCSF’s Pröbstel. “Until now, no one has really studied these IgA-producing plasma cells in the context of disease, but we are now examining them in detail in patients with MS to begin to understand how we might manipulate them to help treat neuroinflammatory disease.”
A key next step for the researchers is to figure out what microbes in the gut promote the generation of immunosuppressive IgA plasma cells. “If we can understand what these cells are reacting to, we can potentially treat MS by modulating our gut commensals,” said Gommerman, referring to the bacteria that live in the healthy gut. “That might be easier than getting drugs into the brain, which is a strategy that hasn’t always worked in MS.”
The study also raises questions about the microbiome and lifestyle choices. Do certain lifestyles nudge some people toward a gut microbiome that allows immunosuppressive plasma cells to flourish? Are specific foods conducive to creating that environment and if so, might a drug or supplement mimic the effect? Genetics are just one factor that affect susceptibility to MS; the current study highlights how non-genetic factors may confer disease resistance.
Gommerman plans to pursue the basic science behind these questions, working with Baranzini and other research groups to bring the findings into the clinical realm. “There is something very critical about how the gut and brain are connected, and we’re starting to unravel the molecular threads behind that clinical observation,” she said. “It’s a great example of how fast science can move.”
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- BRIEF-Anavex Life Sciences Announces Publication Of Foundational Data For Anavex®2-73 In Multiple Sclerosison February 24, 2020 at 9:20 am
Anavex Life Sciences Corp: * ANAVEX LIFE SCIENCES ANNOUNCES PUBLICATION OF FOUNDATIONAL DATA FOR ANAVEX®2-73 (BLARCAMESINE) IN MULTIPLE SCLEROSIS (MS) * ANAVEX LIFE SCIENCES - STUDY ALSO DESCRIBED ...
- Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)on February 24, 2020 at 4:16 am
and European Medicines Agency (EMA) have accepted the company’s Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab (OMB157) ...
- Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX(R)2-73 (blarcamesine) in Multiple Sclerosis (MS)on February 24, 2020 at 4:00 am
Published in Journal of Neuroimmunology, Results Highlight ANAVEX(R)2-73 (blarcamesine) Shown to Protect and Repair Myelin Forming Cells ANAVEX(R)2-73 (blarcamesine) Provides optimal Protection of ...
- U.S. FDA Filing Acceptance and Priority Review for sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosison February 23, 2020 at 10:32 pm
Media Release Copenhagen, Denmark, February 24, 2020 U.S. FDA has accepted, with priority review, the sBLA submitted by Novartis for ...
- NICE Gives Green Light to Multiple Sclerosis Drugon February 21, 2020 at 12:23 am
The National Institute for Health and Care Excellence (NICE) has recommended peginterferon beta-1a (Plegridy, Biogen Idec) as a treatment option for relapsing-remitting multiple sclerosis (MS) for ...
- New hope for multiple sclerosis patientson February 17, 2020 at 4:30 pm
New hope for multiple sclerosis patients Watch "Australian researchers say a drug used to treat rare disease could be used to help treat people with multiple sclerosis", a CBSN video on CBSNews.com.
- Multiple Sclerosis Treatment Market Future Opportunities, Production/Demand Analysis & Outlook To 2026on February 17, 2020 at 3:02 am
In 2020, the global Multiple Sclerosis Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2026, with a CAGR of xx% during 2020-2026. The global Multiple ...
- Multiple Sclerosis Drugs Market 2020: Industry Growth Status, Latest Developments, Revenue, Share And Demands Research Report 2025| QYR Consultingon February 13, 2020 at 1:03 am
QY Research offers its latest report on the global Multiple Sclerosis Drugs market that includes a comprehensive analysis of a range of subjects such as market growth status, competition, segmentation ...
- Consistent Efforts to Find Effective Drugs is Driving Growth of Multiple Sclerosis Drugs Market to Valuation of ~US$ 32 bn by 2027, Finds TMRon February 13, 2020 at 12:30 am
/PRNewswire/ -- Transparency Market Research has been keen following the developments happening across the global Multiple Sclerosis Drugs Market. According ...
- Selma Blair Opens Up About New Multiple Sclerosis Symptomson February 12, 2020 at 6:42 pm
Selma Blair opened up about the realities of multiple sclerosis in a revealing Instagram post. The actress detailed her uncomfortable nights dealing with muscle spasms and difficulty stretching. Selma ...
via Bing News